ISARIC4C Tier 0/CO-CIN fed data dynamically through the Outbreak Data Analysis Platform (ODAP) to Public Health Scotland, Public Health England, SPI-M, NERVTAG and SAGE. SPI-M have been highly productive and published several analysis that informed Policy.
The data were used to inform the NHS England Independent Advisory Group concerning the use of neutralising monoclonal antibodies and anti-viral drugs in high-risk clinical subgroups.
Other key UK policy documents citing ISARIC4C/ODAP data
COVID-19: the green book, chapter 14a.
a. cites Docherty AB, et al. Features of 20133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study https://doi.org/10.1136/bmj.m1985
b. Swann OV, et al. Clinical Characteristics of children and young people admitted to hospital with COVID-19 in United Kingdom: prospective multicentre observational cohort study https://doi.org/10.1136/bmj.m3249
Remdesivir – national prescribing guidance